Health TrialsbyHealthPanel

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

ConditionType 2 Diabetes
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorEli Lilly and Company

About this trial

The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Have type 2 diabetes

Have HbA1c ≥7.5% to ≤10.5% at screening

Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening

Have had a stable body weight for the three months prior to screening

Disqualifiers

Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma

Have a prior or planned surgical treatment for obesity

acute myocardial infarction

cerebrovascular accident (stroke)

Trial design

Design model

Parallel

Treatments tested in this trial

  • LY3457263

    Drug

    Administered SC

  • Placebo

    Drug

    Administered SC

Treatment groups

200 Participants
are divided into 4 treatment groups
Group A: LY3457263 Dose 1Experimental treatment 1 intervention
Group B: LY3457263 Dose 2Experimental treatment 1 intervention
Group C: LY3457263 Dose 3Experimental treatment 1 intervention
Group D: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change from Baseline in Hemoglobin A1c (HbA1c)

Time frame
Baseline, Week 24

Secondary outcomes

1

Change from Baseline in Fasting Serum Glucose

Time frame
Baseline, Week 24
2

Percent Change from Baseline in Body Weight

Time frame
Baseline, Week 24

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Eli Lilly and Company

Lead sponsor

Source ClinicalTrials.gov
Apply now